Experimental drugs that stopped or stalled the progression of Alzheimer's disease in late-stage studies could be launched in five to 10 years, said Simon Lovestone of the Institute of Psychiatry at King's College London. As many as 11 Alzheimer's treatments are in Phase III trials, and about 80 more are in early-stage development.

Full Story:

Related Summaries